| Title | Venue | Year | Impact | Source |
| 3951 | INSIGHTS FROM THE CLINICAL PRESENTATION, DEMOGRAPHICS AND OUTCOME OF PATIENTS WITH COVID-19 VACCINE ASSOCIATED MYOCARDITIS: A SYSTEMATIC REVIEW | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3952 | COVID-19 VACCINES AND ATRIAL FIBRILLATION RISK: A PHARMACOVIGILANCE ANALYSIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3953 | ELEVATED BLOOD VISCOSITY PREDICTS A HIGHER MORTALITY AMONG HOSPITALIZED PATIENTS WITH COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3954 | PREDICTION OF HOSPITALIZATION AND ICU ADMISSION FOR ONTARIO COVID-19 PATIENTS WITH CARDIAC COMORBIDITIES | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3955 | RIGHT VENTRICULAR DILATION AND RV FREE WALL ENHANCEMENT ON ECHOCARDIOGRAM IN COVID-19 PATIENTS: PROGNOSTIC INDICATORS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3956 | ASSOCIATIONS BETWEEN ISCHEMIC CHANGES ON ELECTROCARDIOGRAM AND IN-HOSPITAL MORTALITY IN COVID-19 PATIENTS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3957 | THE IMPLICATIONS OF COVID-19 VACCINATION ON HOSPITALIZATIONS AND CLINICAL OUTCOMES | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3958 | RISK FACTORS OF ARTERIAL THROMBOEMBOLISM IN HOSPITALIZED COVID-19 PATIENTS: A MULTICENTER COHORT STUDY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3959 | EFFICACY AND SAFETY OF LOW DOSE COLCHICINE ON SURROGATE MARKERS OF CARDIOVASCULAR EVENTS IN PEOPLE LIVING WITH HIV RECEIVING ANTIRETROVIRAL THERAPY Background Antiretroviral therapy (ART) reduces morbidity and mortality of people living with human immunodeficiency virus (PLWH) and makes them live longer. The incidence of cardiovascular disease was raised and became one of the leading causes of death in PLWH. Chronic inflammation is one of the mechanisms involving increasing incidence. It was recently showed that colchicine reduced inflammatory markers associated with cardiovascular events and death;however, the study in PLWH is lacking. Methods In a double-blind, randomized controlled trial, we assigned PLWH receiving ART without a history of cardiovascular events to received colchicine 0.6 mg once daily or placebo. The primary endpoint was the mean difference of hs-CRP and IL-6 levels at three months. The secondary endpoint was to access safety outcomes. Results A total of 212 patients were screened for hs-CRP level. There were 59 patients who had hs-CRP more than 2 mg/L, and 47 patients were included in this study, 23 PLWH in the colchicine group and 24 PLWH in the placebo group. Because of the pandemic of COVID-19, only 38 PLHW could visit the hospital for the final blood sampling. The median age (interquartile range) was 49.3 (46.1 - 53.3) years in the colchicine group and 48.5 (43.8 - 55.1) years in the placebo group. The mean hs-CRP and IL-6 were 5.38 ± 5.96 mg/L and 3.37 ± 3.94 pg/mL in the colchicine group, and 4.25 ± 2.71 mg/L and 2.34 ± 1.14 pg/mL in the placebo group. At the 12-week follow-up, the mean difference of hs-CRP level was -1.01 ± 3.2 mg/L in the colchicine group and 0.06 ± 5.9 mg/L in the placebo group (P = 0.487). The mean difference of IL-6 level was -0.72 ± 2.3 pg/mL in the colchicine group and -0.07 ± 1.29 pg/mL in the placebo group (P = 0.298). There were gastrointestinal (GI) side effects of 16.7% in the colchicine group and 25.0% in the placebo group. Conclusion The trend of hs-CRP and IL-6 levels were lower in the colchicine group comparing with the placebo but could not achieve statistically significant. This could be from the insufficient power of the study due to the small sample size. The GI side effects from low-dose colchicine were not significantly different from placebo. | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3960 | ASSOCIATION OF NEW ONSET ATRIAL FIBRILLATION WITH ALL-CAUSE MORTALITY IN COVID-19 PATIENTS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3961 | EVALUATION OF MICROVASCULAR FUNCTION AND SYSTEMIC INFLAMMATION IN THE ACUTE PHASE OF COVID-19 AND 1 YEAR AFTER RECOVERY: INSIGHTS INTO THE PATHOPHYSIOLOGY OF POST-COVID-19 SYNDROME | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3962 | OUT-OF-HOSPITAL CARDIAC ARREST DURING THE COVID-19 PANDEMIC: RESULTS FROM THE NORTHEAST GEORGIA CARDIAC ARREST REGISTRY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3963 | CHARACTERIZATION OF THE FIRST 391 REPORTS OF MYOCARDITIS AFTER MRNA COVID-19 VACCINES SUBMITTED TO THE VACCINE ADVERSE EVENT REPORTING SYSTEM-UNITED STATES | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3964 | MYOCARDIAL INFLAMMATION IN RECOVERED COVID-19 PATIENTS: HAS THIS BEEN OVERESTIMATED? | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3965 | PRE-ADMISSION ORAL ANTICOAGULATION IS ASSOCIATED WITH FEWER THROMBOTIC COMPLICATIONS IN PATIENTS ADMITTED WITH COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3966 | INFLAMMATION AND VASCULAR REMODELING IN COVID-19 HEARTS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3967 | ACCURACY OF THE GRACE SCORE IN PREDICTING MORTALITY IN PATIENTS WITH COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3968 | THE IMPACT OF THE COVID-19 PANDEMIC ON MANAGEMENT OF CHRONIC CARDIOVASCULAR DISEASE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3969 | SOLUBLE P-SELECTIN, PLATELET ACTIVITY AND RISK OF MORBIDITY AND MORTALITY IN COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3970 | CORONARY CONSIDERATIONS FOR THROMBOSIS IN COVID-19 NSTEMI | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3971 | VENTRICULAR SEPTAL DEFECT AFTER MYOCARDIAL INFARCTION: WHEN TO NOT STAY AT HOME DURING THE COVID-19 PANDEMIC | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3972 | COVID-19 FULMINANT MYOCARDITIS PROGRESSING TO CARDIAC TAMPONADE IN LESS THAN 24 HOURS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3973 | POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME DUE TO COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3974 | BRUGADA EKG PATTERN IN A PATIENT WITH COVID-19 INFECTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3975 | AN INTERESTING CASE OF MYOCARDITIS IN A 60 YEAR OLD MALE FOLLOWING ADMINISTRATION OF FIRST DOSE OF COVID-19 MRNA VACCINE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3976 | DYSAUTONOMIA RESULTING FROM POST-VIRAL SYNDROME: A LONG-COVID CLINICAL QUANDARY | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3977 | RIGHT VENTRICULAR THROMBUS IN A TEENAGER SECONDARY TO COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3978 | IMPACT OF COVID-19 PANDEMIC IN ACUTE CORONARY SYNDROMES IN PANAMA | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3979 | LEFT VENTRICULAR THROMBUS PRESENTING AS MULTIPLE EMBOLIC SHOWER IN COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3980 | FULMINANT MYOCARDITIS AFTER RECOVERY FROM COVID-19 INFECTION: A CASE REPORT | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3981 | SPONTANEOUS CORONARY ARTERY DISSECTION PRESENTING AS ACUTE ST SEGMENT ELEVATION INFERIOR WALL MYOCARDIAL INFARCTION IN PATIENT WITH COVID-19. ARE PERICYTES THE MISSING LINK? | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3982 | PREDICTIVE VALUE OF LUNG AND MYOCARDIAL PERFUSION IMAGING IN ACUTE COVID-19 INFECTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3983 | MYOCARDITIS FROM COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3984 | SIMULTANEOUS TAKOTSUBO CARDIOMYOPATHY WITH HIGH AV BLOCK DURING ACUTE SARSCOV-2 VIRAL INFECTION: A RARE COMPLICATION OF COVID-19 | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3985 | CARDIAC SYMPTOMS PRECIPITATED BY COVID INFECTION: OUT OF FRYING PAN INTO THE FIRE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3986 | FAST AND DIZZY: POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME IN THE SETTING OF COVID-19 INFECTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3987 | A COMPLICATED CASE OF INCIDENTAL PERICARDIAL EFFUSION IN RECENT SARS-COVID-19 INFECTION Background: SARS-COV2 enters the host cells via angiotensin-converting enzyme 2 receptor, which is heavily expressed by the lungs and heart. Few cases of pericarditis in COVID-19 infection were reported. Case: A 55-year-old Hispanic male with recent flu-like symptoms presented with abdominal pain. CT abdomen showed large pericardial effusion with 4cm thickness. An inferior echo showed effusion without signs of tamponade. He was discharged with NSAID and diuretics. Eleven days later, he returned with worsening dyspnea due to bilateral pulmonary emboli. Repeat echo significant for right atrial and ventricular collapse. Emergent pericardial window was performed with 1.2L dark bloody pericardial fluid was drained. Fluid cytology and cultures were negative. Cell analysis suggested transudative effusion. SARS-COVID-19 IgG antibody was positive. The etiology of the effusions is likely to be viral pleuropericarditis from recent COVID-19 infection. Decision-making: Multiple case reports had been published showing a high risk for pericardial effusion to convert into tamponade requiring emergent intervention. There has also been a higher risk for biventricular failure on COVID-19 patients. Knowing this risk, the patient presented should have had an intervention earlier during the first visit or closer monitoring. Conclusion: It is important to know the complications of COVID-19 infection including pericarditis and high risk for progression into tamponade, requiring prompt intervention. [Formula presented] | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3988 | RELAPSING PERICARDITIS FOLLOWING COVID-19 VACCINE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3989 | MYOCARDITIS MASQUERADING AS MEDIAN ARCUATE LIGAMENT SYNDROME: VACCINE induced MYOCARDITIS IN A YOUNG FEMALE Background: Acute myocarditis is a rare complication of messenger RNA (mRNA) COVID-19 vaccination. Case: A 36-year-old female with hypertension, smoking, prior alcohol use, chronic pancreatitis and prior COVID-19 infection was transferred for surgical intervention for median arcuate ligament syndrome (MALS). She noted abdominal pain, chest discomfort, dyspnea, orthopnea, and lower extremity edema which began 5 days after the second dose of BNT162b2 COVID-19 vaccine. Physical exam revealed rales, abdominal distention and pitting edema. 12 lead ECG showed a nonspecific ST abnormality. Troponins were 19,222 ng/L (ref < 17 ng/L). Brain natriuretic peptide level was 4734 pg/mL (ref<100 pg/mL). Testing for active COVID-19 infection was negative. Chest x-ray demonstrated a right pleural effusion. Transthoracic echocardiogram revealed apical wall akinesis. Cardiac catheterization showed normal coronary vasculature. Cardiac MRI showed late gadolinium enhancement (LGE) in the basal anterolateral, mid-anterior and midanterolateral walls. Decision-making: Myocarditis should be suspected with elevated cardiac biomarkers, new unexplained heart failure and normal coronary angiography. Despite apical dysfunction, Takutsubo (stress) cardiomyopathy was less likely given CMR findings of LGE. Acute COVID-19 infection is well known to be associated with acute myocarditis but testing was negative. Testing for other potential etiologies (HIV, EBV, toxicology) was also negative. There was no history of collagen-vascular disease. Surgical and gastrointestinal consultations noted symptoms were consistent with acute heart failure rather than MALS. Timing was most consistent with vaccine induced myocarditis given onset within days of second injection with an mRNA vaccine. Based on the above findings decision was made to begin the patient on guideline directed medical therapy (GDMT) with diuretics, ace inhibition and beta blockade. Conclusion: While most common in young males, myocarditis following shortly after mRNA vaccine administration should be considered in patients without another etiology and with appropriate timing of symptom development. Most patients will improve with GDMT. | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3990 | ACUTE MANAGEMENT OF MYOCARDITIS DUE TO MULTI-SYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2 INFECTION | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3991 | COVID-19 MYOPERICARDITIS- NEW STORMS, NEW NORMS? | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3992 | COVID-19 INDUCED MYOPERICARDITIS AND CARDIAC TAMPONADE: A DIAGNOSTIC DILEMMA | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3993 | ATRIAL SEPTOSTOMY USED TO TREAT ACUTE RIGHT HEART FAILURE IN COVID-19 PATIENT ON ECMO | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3994 | COVID induced LEFT VENTRICULAR ANEURYSM WITH SYSTEMIC EMBOLI SHOWERS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3995 | CARDIOMYOPATHY AND COVID-19: A CASE OF MULTIORGAN DYSFUNCTION IN A YOUNG PATIENT | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3996 | SYSTEMIC THROMBOEMBOLISM SECONDARY TO ACUTE MYOCARDIAL INFARCTION IN A PATIENT WITH CORONAVIRUS DISEASE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3997 | COVID-19 ASSOCIATED ACUTE THROMBOTIC ST-ELEVATION MYOCARDIAL INFARCTION IN AN ADOLESCENT: MANAGEMENT WITH INTRACORONARY AND SYSTEMIC THROMBOLYSIS | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3998 | ACUTE ST ELEVATION MYOCARDIAL INFARCTION (MI) IN YOUNG HEALTHY PATIENT FOLLOWING (MRNA) COVID-19 VACCINE | J Am Coll Cardiol | 2022 | | CORD-19 |
| 3999 | THE HEART OF AN ATHLETE POST-COVID: WHAT'S NEXT? | J Am Coll Cardiol | 2022 | | CORD-19 |
| 4000 | POST-COVID-19 MYOPERICARDITIS INDUCED CARDIOMYOPATHY SECONDARY TO MULTISYSTEM INFLAMMATORY SYNDROME IN ADULTS (MIS-A) | J Am Coll Cardiol | 2022 | | CORD-19 |
